DOWNSTREAM PROCESSING FEATURED ARTICLES
Genmab A/S announced recently additional details concerning the subscription of shares by Johnson & Johnson Development Corporation (JJDC) as part of the global license and development agreement for daratumumab (HuMax-CD38) between Genmab (see Genmab's Company Announcement 20) and Janssen Biotech, Inc., one of the Janssen Pharmaceutical companies of Johnson & Johnson.
-
NGM Enters Agreement With Janssen To Discover And Develop Novel Therapeutics For Diabetes
NGM Biopharmaceuticals, Inc. announced recently that it has signed a worldwide agreement with Janssen Pharmaceuticals, Inc. to discover and develop novel therapeutics for the potential treatment of Type 2 diabetes and other metabolic diseases.
-
Cortex Biochem Awarded Patent Cortex Biochem(TM) Inc., a global leader in developing magnetic particle technology and products used in genomic research and clinical diagnostics, announced it has received a U.S. patent for its MagaZorb(R) Nucleic Acid (DNA/RNA) Isolation and Purification System...
-
Studies Put Kibosh On Statins For Breast Cancer Prevention
New data from the Women’s Health Initiative dash cold water on the idea that statin therapy reduces breast cancer risk.The updated WHI findings showed no association between prior statin use and breast cancer risk in nearly 155,000 postmenopausal study participants followed prospectively for an average of 10.8 years.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
![Optimized Purity And Recovery Of A Monoclonal Antibody Using Mixed-Mode Chromatography Media]( "Optimized Purity And Recovery Of A Monoclonal Antibody Using Mixed-Mode Chromatography Media")
Optimized Purity And Recovery Of A Monoclonal Antibody Using Mixed-Mode Chromatography MediaMonoclonal antibodies (mAbs) remain a predominant class of therapeutic protein products on the market because of their wide range of applications in disease treatment and diagnosis. Over the years, upstream technology advancements have helped improve the titer of target antibodies, from merely 1 g/L two decades ago to 10–13 g/L in fed-batch processes and up to 25 g/L in perfusion cultures today (Gronemeyer et al. 2014).
-
Rapid Chemically-Defined Feed Media Development to Improve Simulated Cell Culture Processes
Implementing an optimized feed medium may be the most effective alternative for modifications to the growth medium in an existing process.
-
Micro-Volume Determination Of Labeling Efficiency In A Standard Microplate Reader
A variety of methods and reagents have been developed to efficiently label biomolecules. By Peter J. Brescia, Applications Scientist, BioTek Instruments, Inc.
-
Comparability Of The Cell-Freeze® (Charter Medical) Freezing Bag To The Cryocyte™ (Baxter) Bag For Cryogenic Storage Of Human Hematopoietic Progenitor Cells Successful cryopreservation of hematopoietic progenitor cells (HPC) is dependent upon a number of factors, including the biopreservation media, freezing rates, and storage using sterile, cryogenically durable storage bags. The Cell-Freeze® cryogenic storage containers are 510(k) cleared for storage, preservation and transfer of hematopoietic progenitor stem cells (HPC’s). By Charter Medical, Ltd.
-
Automated Bioluminescent ADCC Reporter Bioassay Using Bioengineered Jurkat Cells
Pharmaceutical companies are increasingly exploring new biologic and biosimilar products, and thus increasing monoclonal antibody (mAb) immunotherapeutic research. By Tracy Worzella, Promega Corporation and Brad Larson, Applications Department, BioTek Instruments, Inc.
-
![450x300 drug model-inside protein molecule]( "Important Parameters For Packing Nuvia HR-S Resin At Process Scale")
Important Parameters For Packing Nuvia HR-S Resin At Process ScaleProcess-scale production typically involves more than one column. The packing quality of each column affects the efficiency of the whole workflow and is an important validation criterion.
DOWNSTREAM PROCESSING MULTIMEDIA
Bioprocess With The Bozenhardts is back, with a fresh episode packed with advice from Herman and Erich on the selection of filling systems for biopharmas. Listen in as the Bozenhardts give us an update on the process, logistics, and administration trends that are informing filling system decisions today, and offer direction on making choices that will prepare you for the fast-advancing therapies of tomorrow.
Bio-Rad now offers two very high capacity ion exchangers: Nuvia S, which can be used for capture and/or intermediate polishing; and Nuvia Q, which can be used for intermediate and/or final polishing.